Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly


Crinetics Pharmaceuticals reports that paltusotine, an oral, once-daily investigational compound, met the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study

Crinetics Announces September 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces September 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Announces August 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces August 2023 inducement grants: the stock options were granted as inducements material to seven employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals reported financial results and provided an update on second quarter 2023 progress

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly


Crinetics Pharmaceuticals is hosting a webinar on the acromegaly treatment landscape and unmet need with KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital